New Nicotinic Acid-based Hydrogel: Swelling and Insulin Uptake Studies

Priyanka Dogra 1, Sunita Ranote 1,2, Kiran Kumar 1,2, Sandeep Chauhan 1,2, Ghanshyam S. Chauhan 1,*

1. Department of Chemistry, Himachal Pradesh University, Shimla, 171 005 India
2. Correspondence: ghanshyam_in2000@yahoo.com; ghanshyamschauhan@gmail.com (G.S.C.);

Abstract: Designing a target-specific insulin delivery via the oral route or the non-invasive mode using the polymer-based drug delivery systems is a research area attracting the researchers’ attention worldwide. In the present short communication, we report a new nano-system with a bioactive component, nicotinic acid (NA). It was conjugated via the lipase-catalyzed reaction with polyethylene glycol (PEG 400). NA and PEG were taken in a 1:1 molar ratio along with 1% of lipase and reacted at 45 °C. The PEGylated-NA was characterized for its structural aspects using different techniques. Swelling studies were carried out at pH 6.0, 7.0, and 9.0. The order of water uptake was 6.0 > 7.0 > 9.0. The PEGylated-NA was evaluated as a platform to load insulin at pH 7.4 and the physiological temperature of 37 ºC. It showed a high affinity for insulin with uptake of 82.68% with an adsorption capacity of 206.7 mg/g.

Keywords: nicotinic acid; PEG-400; swelling behavior; insulin loading.

© 2022 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

In recent times, diabetes has been a serious problem challenging health management throughout the world [1-3]. Insulin is a regulatory hormone that plays an important role in controlling glucose homeostasis. It also allows cells present in the liver and muscle to circulate sugar from the blood and store it as glycogen in the liver and muscles [4]. Decreased level of insulin in the body causes diabetes mellitus; hence, its use in treatment is recommendable through the intravenous route to the patients to avoid side effects [5]. Targeted insulin delivery is the most effective therapy to treat diabetes [6]. The use of nano-insulin has become an area of much interest [7]. Drug delivery via the oral route is the most promising mode, considering its non-invasive operation, which leads to minimum discomfort for patients. Polymeric hydrogels with a high water retention capacity are good candidates to overcome hurdles in the way of effective and site-specific drug release [8-10].

Conjugation of drugs with bioactive compounds leads to their targeted delivery directly to various organs or tissues by the controlled release that improves the pharmacokinetics of drug release and diminishes various side effects [11]. Hence, there is a need for some bioactive compounds which can decorate these drugs for target-specific delivery of drugs. For the targeted drug delivery system, conjugation of drug with polyethylene glycol (PEG) is clinically approved by FDA for humans because of its non-toxicity, non-immunogenicity, non-antigenic and amphiphilic nature with repeated ethylene oxide sub-units [12,13]. Conjugation of drug
with PEG-oligocholic acid increases circulation time, leading to sustained delivery to the target, as exemplified with PEG/poly(MAAC) reported to show resistance towards plasma [14]. There are many reports in which conjugation of PEG with various drugs resulted in controlled target-specific drug delivery in the literature. PEG attached with oligo acid and dendrimers has been reported for the targeted specific delivery of drugs [15,16]. Many other reports have been cited in the literature for sustained drug delivery by the covalent attachment of bioactive compound with PEG, which is clinically considered a potent technique [17,18]. In a study, PEGylated starch acetate nanoparticles were reported for the controlled delivery of insulin [19]. PEGylated chitosan hydrogels and cyclodextrin were also reported to enhance pharmaceutical activity and, consequently, sustain insulin release [20]. Given the above discussion, it is evident that the conjugation of some bioactive compounds with PEG is a more potent mode for site-specific drug delivery. One study used folic acid as a bioactive component of the modified PEG-functionalized hydroxyapatite nanoparticles in paclitaxel delivery with enhanced activity [21]. The upload of insulin for oral delivery on biopolymers or bioactive materials has been reported in the literature [22-28]. In the present study, nicotinic acid (NA), a vitamin B, was PEGylated. It has lower molecular weight, higher water solubility, and a minimum side effect [29]. Its lower molecular weight is a positive feature for targeting molecules, a necessary and sufficient condition for conjugation. In a report, NA was used to investigate insulin resistance in the body [30].

Given the previous work based on drug delivery from different biocompatible polymers [31-35], we have synthesized a versatile nano-sized hydrogel to modify NA by PEGylation and utilize the resultant polymer as vehicles for the upload of insulin. The modified PEG was characterized by Fourier transform infrared (FTIR), 1H nuclear magnetic resonance spectroscopy (1H- NMR), X-ray diffraction (XRD), and transmission electron microscopy (TEM). The swelling behavior of PEGylated-NA was studied to justify its drug uptake and release profiles. We are submitting this report as short communication as the release profile of the insulin-loaded material has not yet been carried out. There is no similar report in the literature.

2. Materials and Methods

2.1. Materials.

Nicotinic acid (NA), triacylglycerin lipase, ethylene Glycol (EG) (Himedia Lab. Pvt. Ltd., India), polyethyleneglycol (PEG_{400}) (Merck, Schuchardt, Germany), insulin human mixtard (Torrent Pharmaceuticals Ltd., India), sodium hydroxide, hydrochloric acid, di-sodium hydrogen orthophosphate anhydrous (Na_{2}HPO_{4}), sodium dihydrogen orthophosphate dehydrate (NaH_{2}PO_{4}.2H_{2}O) (S.D Fine-Chemicals Ltd.), all of the analytical grade, were used as received.

2.2. Synthesis of PEGylated-NA.

NA was modified by the PEGylation method. Lipase (1% by weight of total reaction mixture) was used as a catalyst in the esterification reaction between NA and PEG (1:1 molar ratio) at 45 °C for 8 h in Chemical Reactor (Miniblock™, Germany). The synthesized ester, named PEGylated-NA, was washed thoroughly (4 times) to remove unreacted materials. After purification, it was refluxed by thermal treatment under temperature 70 °C in the deionized
water to remove unreacted reaction components. PEGylated-NA was separated by washing with acetone and dried in an oven (Scheme 1).

![Scheme 1. Synthetic route of PEGylated-NA from nicotinic acid.](image)

2.3. Characterization of synthesized products.

Synthesized product was characterized by Fourier transform infrared spectroscopy (Nicollet 5700); and transmission electron microscope images of the (Joel Stereoscan-150). Scanning electron microscopy of the synthesized sample was recorded on (SEM QUANTA 250 D9393).

2.4. Swelling study.

The swelling behavior of the PEGylated-NA was studied as a function of pH and time at 37 °C. A known weight (100 mg) of the material was immersed in the distilled water to optimize the period of swelling. Furthermore, the effect of pH on swelling was observed with respect to time (15–360 min) in buffer solutions of pH 6.0–9.0. The swollen polymer was taken out from the solution, wiped off, and then weighed immediately to calculate %swelling/water uptake ($P_s$) as [36]:

$$P_s (%) = \frac{\text{Weight of swollen hydrogel} - \text{Weight of dry hydrogel}}{\text{Weight of dry hydrogel}} \times 100$$  \hspace{1cm} (1)

Fick’s law was applied to determine the diffusion and swelling kinetics of the polymer and is expressed as [37,38]:

$$f = \frac{M_t}{M_e} = kt^n$$  \hspace{1cm} (2)

The linear form of Fick’s law is represented as:

$$\ln f = \ln k + n \ln t$$  \hspace{1cm} (3)

where $f$, $M_t$, $M_e$, $k$, and $n$ are the swelling fraction, swollen mas at a time 't', mass at equilibrium, kinetic constant, and diffusion exponential, respectively. The slope of the graph $\ln f$ vs. $\ln t$ gives the value of $n$. If $n = 0.5$, the solvent diffusion or transport rate is much higher than the rate of relaxation process of polymeric chains, which means swelling kinetics obey the Fickian model (Case I transport). For $n = 1$, the swelling kinetics obey the non-Fickian model (Case II), where solvent diffusion through the polymer is very fast compared to the relaxation rate, for $0.5 < n < 1.0$, the swelling kinetics follow anomalous transport or non-Fickian model where swelling, and diffusion rate are analogous. For $n > 1.0$, swellings kinetics obey Super Case II transport where solvent transport occurs along with breaking of the polymeric chains.
2.5. Insulin loading study.

Accurately weighed, 100 mg of insulin was dissolved in a minimum amount of distilled water in different measuring flasks. The volume of the solution was made up to 100 mL for each insulin solution (250 ppm) using the phosphate buffer pH 7.4. After separating the insulin-PEGylated-NA from the drug solution, the optical density (OD) values of the solution containing the residual insulin were measured on a spectrophotometer at 660 nm. The hydrogels were washed thrice with the distilled water and were later dried under vacuum. The drug loading capacity (q) and entrapment/encapsulation efficiency (EE%) of the hydrogel were calculated from the following equations [39]:

\[
q = \frac{T_c - R_c}{W} \times V \quad (4)
\]

\[
EE(\%) = \frac{T_c - R_c}{T_c} \times 100 \quad (5)
\]

where \(T_c\) is the total concentration of the drug solution in ppm taken for loading, \(R_c\) is the concentration of rejected/unloaded drug in solution, and \(V\) is the initial volume of insulin solution. Evidence of the insulin-loaded sample was obtained by recording FTIR spectra in the 4000-500 cm\(^{-1}\) range in KBr on Nicolet 5700 spectrophotometer.

3. Results and Discussion

3.1. Characterization of polymers by different techniques.

Conformation of synthesis of new PEGylated-NA by covalent conjugation of PEG with NA, loading of insulin on PEGylated-NA was obtained from the FTIR spectroscopy (Figure 1). FTIR spectra of PEGylated-NA shows bands at 3142 cm\(^{-1}\) (C–H stretching vibrations), 2954 cm\(^{-1}\) (CH\(_2\) symmetric stretching vibrations), 1639 cm\(^{-1}\) (C=O stretching vibrations of ring), 1580 cm\(^{-1}\) and 1406 cm\(^{-1}\) (C=C stretching vibrations), 1381 cm\(^{-1}\) (CH\(_3\) symmetric bending vibrations), 1259 cm\(^{-1}\) and 1119 cm\(^{-1}\) (two strong C–O stretching bands due to asymmetric and symmetric stretching C–O–C group), 1059 cm\(^{-1}\) (C–H in-plane bending), 961 cm\(^{-1}\) (C–O–C stretching vibrations) and 844 cm\(^{-1}\) (C–H binding vibrations) \([40,41]\) (Figure 1a). Insulin has a large number of functional groups, and its loading by the PEGylated-NA affects the intensity and stretching mode. After insulin uptake, all the bands remain preserved with a slight change in their position and intensity along with the appearance of the new bands at 3290 cm\(^{-1}\), 1659 cm\(^{-1}\), and 1570 cm\(^{-1}\) due to N–H, amide I, and amide II bands (C=O stretching vibrations) which confirms loading of insulin onto PEGylated-NA (Figure 1b) \([42]\).
Figure 1. FTIR spectra of (a) PEGylated-NA and (b) insulin-loaded PEGylated-NA.

TEM/SEM images were used to study and reveal the polymeric structures' shape, size, or surface morphology. It provides evidence of changes affected in the surface morphology after derivatization. SEM image of the PEGylated-NA shows a long porous space between the molecules (Figure 2a). After insulin adsorption, the surface becomes less porous and denser, revealing the absorption of insulin on the PEGylated-NA matrix (Figure 2b).

Figure 2. SEM images of (a) PEGylated-NA and (b) insulin-loaded PEGylated-NA.

Figure 3. TEM images of (a) PEGylated-NA and (b) insulin-loaded PEGylated-NA.
TEM images were recorded to study and reveal the shape and size of the polymeric structures pre– and post-drug loading. The TEM image of the PEGylated-NA shows a long smooth nanorod-type structure (Figure 3a). The size of these rods is < 100 nm. Nanorod shape or structure and smooth surface result from the self–assembly of the PEG chains on the one end and residual NA moiety at the other end. Later, in insulin-loaded PEGylated-NA, insulin molecules get deposited on the PEGylated-NA surface, which is evident from Figure 3b.

3.2. Swelling study of PEGylated-NA.

The PEGylated-NA behaves as hydrogel by absorbing a large amount of water (Figure 4). Such property augurs well for its use as a drug delivery device—the appreciable high water uptake results from the self-assembled structure of the amphiphilic PEG chains. In the case of PEGylated-NA, water molecules interact with the PEG chains.

![Figure 4](https://biointerfaceresearch.com/)

**Figure 4.** Pₜ of PEGylated-NA at different pH as a function of time at 37 °C.

![Figure 5](https://biointerfaceresearch.com/)

**Figure 5.** Swelling kinetic plots at different pHs.

The maximum equilibrium swelling of 1295% was attained within 300 min at 37 °C. Structure and environment-dependent swelling has been reported in the literature for PEG microspheres [43]. Along with the high-water uptake by the PEGylated-NA, another important attribute of this nanomaterial is its stimuli-responsive swelling. These two features are related
to the high drug loading and the site-specific drug release. PEGylated-NA can partition a large amount of drug or bioactive molecules from water and release that at an appropriate site depending on the stimuli-responsive nature, or pH in this case. The maximum swelling was observed with the order of pH responsiveness to water uptake as the swelling order was found to be $6.0 > 7.0 > 9.0$ at 37 ºC (Figure 4). From Fick's law, the value of $n$ was found to be 1.193, 1.28, and 1.18 for pH 6, 7, and 9, respectively, that swelling kinetics follows Super Case II transport of solvent (Figure 5).

### 3.3. Preliminary investigation of insulin uptake.

Loading insulin onto the PEGylated was carried out at the maximum solubility of the drug at pH 7.4 under the phosphate buffer saline (PBS) medium and at the physiological temperature of 37 ºC. It has uptake up to 82.68% with $q$ value up to 206.7 mg/g. These values are far higher than reported in an earlier study [34]. High loading of insulin has many pharmaceutical applications as a single dose large amount of drug for a large therapeutic range can be used for the localized use at a part of the body (Figure 6).

![Figure 6. Insulin uptake study by PEGylated-NA.](image)

A comparative study of the insulin uptake capacity and entrapment efficiency of the synthesized hydrogel with other polymeric systems is shown in Table 1, revealing that the synthesized hydrogel is an efficient drug delivery device for insulin delivery.

| S. No. | Polymeric materials | EE (%) | References |
|-------|---------------------|--------|------------|
| 1.    | Chitosan/TPP nanoparticles | 69.37 ± 4.71 | [42] |
| 2.    | mPEG10%-CS-GMC10% | 71.3 ± 1.02 | [44] |
| 3.    | Bipolymer lipid hybrid nanocarrier | 50.94 | [45] |
| 4.    | Chitosan hydrogels | 78.0 ± 0.7 | [46] |
| 5.    | Polycation complexes | > 50.0 | [47] |
| 6.    | Carboxymethyl chitosan nanocarriers | 83.78 ± 3.73 | [48] |
| 7.    | Polyelectrolyte complex (Ins/NGs-PEC) | 85.2 | [49] |
| 8.    | PEGylated-NA | 82.68 | Present study |
4. Conclusions

The present work aimed to design a versatile hydrogel by PEGylation of nicotinic acid (NA), without using a crosslinker via the lipase-catalysis. The PEGylated-NA has nanorod shaped structure with smooth surface morphology. These undergo high swelling when studied under media of different pH, from 6.0-9.0. The PEGylated-NA absorbs 82.68% of insulin at pH 7.4 and 37 °C. These NA-based nanorods have attractive applications in insulin release studies.

Funding

This research has no external funding.

Acknowledgments

The authors are grateful to the Department of Chemistry, Himachal Pradesh University, for providing facilities to carry out this work.

Conflicts of Interest

There is no conflict of interest for this work.

References

1. Lisa, D.; Andreia, F.D. M.; Silvia, G.D.L.; Lucy, H.; Esther, J; Abha, K.; Jinnan, L.; Inga, P.; Lorenzo, P.; Phil, R.; Els, S.; Beatriz, Y.J.; Mike, W.; Wen Y.; Jing, L.; Sue, P.; Anne, W. O. Merry RG IDF Diabetes Atlas 2019, 9th ed.
2. WHO. Global Report on Diabetes 2016, https://apps.who.int/iris/bitstream/handle/10665/204871/9789241565257_eng.pdf.
3. Marbini, M.H.; Amiri, F.; Hezaveh, Z.S. Dietary Glycemic Index, Glycemic Load, Insulin Index, Insulin Load And Risk of Diabetes-Related Cancers: A Systematic Review of Cohort Studies. Clínic Nut ESPEN 2021, 42, 22–31, https://doi.org/10.1016/j.clnesp.2021.02.008.
4. Paduraru, D.N.; Alexandra, B.; Ion, D.; Dumitrascu, M.C.; Nitipir, C.; Stoian, A.P.; Hainarosie, R.; Bolocan, A.; Orlov, C.; Badiu, D.C.; et al. Latest news and trends in what concerns the risk factors of endometrial cancer. Romanian Biotechnological Letters 2018, 23, 14056-14066.
5. Hashide, R.; Yoshid, K.; Hasebe, Y.; Takahashi, S.; Sato, K.; Anzai, J. Insulin-Containing Layer-by-Layer Films Deposited on Poly(lactic acid) Microbeads for pH-Controlled Release of Insulin. Colloid B: Biointer 2012, 89, 242–247, https://doi.org/10.1016/j.colsurfb.2011.09.023.
6. Wang, J.; Yu, J.; Zhang, Y.; Zhang, X.; Kahkoska, A.R.; Chen, G.; Wang, Z.; Sun, W.; Cai, L.; Chen, Z.; Qian, C.; Shen, Q.; Khademhossein, A.; Buse, J.B.; Gu, Z. Charge-Switchable Polymeric Complex for Glucose-Responsive Insulin Delivery in Mice and Pigs. Sci Adv 2019, 5, 4357, https://doi.org/10.1126/sciadv.aaw4357.
7. Zu, Y.; Zang, Y.; X.; Shan, C.; Zu, S.; Wang, K.; Li, Y.; Long, Ge, Y. Preparation and Characterization of Chitosan–Polyvinyl Alcohol Blend Hydrogels for the Controlled Release of Nano-Insulin. Int J Biol Macromol 2012, 50, 82–87, https://doi.org/10.1016/j.ijbiomac.2011.10.006.
8. Mansoor, S.; Kondiah, P.P.D.; Choonara, Y.E.; Pillay, V. Polymer-based Nanoparticle Strategies for Insulin Delivery. Polymers 2019, 11, 1380, https://doi.org/10.3390/polym11091380.
9. Mansoor, S.; Kondiah, P.P.D.; Choonara, Y.E. Advanced Hydrogels for the Controlled Delivery of Insulin. Pharmaceutics 2021, 13, 2113, https://doi.org/10.3390/pharmaceutics13122113.
10. Qi, X.; Yuan, Y.; Zhang, J.; Bulte, J.W.M.; Dong, W.; Oral Administration of Salecan-based Hydrogels for Controlled Insulin Delivery. Agric Food Chem 2018, 66, 10479–10489, https://doi.org/10.1021/acs.jafc.8b02879.
11. Thakur, A.; Ranote, S.; Kumar, D.; Bhardwaj, K. K.; Gupta, R.; Chauhan, G.S. Synthesis of a PEGylated Dopamine Ester with Enhanced Antibacterial and Antifungal Activity. *ACS Omega* 2018, 3, 7925–7933, https://doi.org/10.1021/acsomega.8b01099.

12. Harris, J.M.; Martin, N.E.; Modi, M. PEGylation: A Novel Process for Modifying Pharmacokinetics. *Clin Pharmacokinet* 2001, 50, 539–551, https://doi.org/10.2165/00003088-20014007-00005.

13. Greenwald, R.B.; Choe, Y.H.; McGuire, J.; Conover, C.D. Effective Drug Delivery by PEGylated Drug Conjugates. *Adv Drug Deliv Rev* 2003, 55, 217–250 https://doi.org/10.1016/s1061-4099(02)00180-1.

14. Xiao, K.; Luo, J.; Li, Y.; Lee, J.S.; Fung, G.; Lam, K.S. PEG-oligocholic Acid Telodendrimer Micelles for the Targeted Delivery of Doxorubicin to B-Cell Lymphoma. *J Control Release* 2011, 155, 272–281, https://doi.org/10.1016/j.jconrel.2011.07.018.

15. Kaminskas, L.M.; McLeod, V.M.; Kelly, B.D.; Cullinane, C.; Sberna, G.; Williamson, M.; Boyd, B.J.; Owen, D.J.; Porter, C.J.H. Doxorubicin-Conjugated PEGylated Dendrimers Show Similar Tumoricidal Activity but Lower Systemic Toxicity when Compared to PEGylated Liposome and Solution Formulations in Mouse and Rat Tumour Models. *Mol Pharm* 2012, 9, 422–432, https://doi.org/10.1021/mp200522d.

16. Pastoriza, C.L.; Todoroff, J.; Vanbever, R. Delivery Strategies for Sustained Drug Release in the Lungs. *Adv Drug Deliv. Rev* 2014, 75, 81–91, https://doi.org/10.1016/j.addr.2014.05.017.

17. Banerjee, S.S.; Aher, N.; Patil, R.; Khandare, J. Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design and Applications. *J Drug Deliv* 2012, 103, 17–27.

18. Bailon, P.; Won, C.-Y. PEG-modified Biopharmaceuticals. *Expert Opin Drug Deliv* 2009, 6, 1–16, https://doi.org/10.1517/17425240802650568.

19. Minimol, P.F.; Paul, W.; Sharma, C.P. PEGylated Starch Acetate Nanoparticles and Its Potential Use for Oral Insulin Delivery. *Carbohydr Polym* 2013, 95, 1–8, https://doi.org/10.1016/j.carbpol.2013.02.021.

20. Casettari, L.; Vilasiliu, D.; Castagnino, E.; Stolnik, S. PEGylated Chitosan Derivatives: Synthesis, Characterizations and Pharmaceutical Applications. *Prog Polym Chem* 2012, 37, 659–685, https://doi.org/10.1016/j.progpolymsci.2011.10.001.

21. Devanand, G.; Ramsamy, S.; G. Avadhani, S.; Ramakrishnan, V.; Kumar, J. Surface Modification of Paclitaxel Drug Delivery of Folic Acid Modified Polyethylene Glycol Functionalized Hydroxypatite Nanoparticles. *Powder Technol* 2013, 235, 437–442.

22. Gholami, S.; Zarkesh, I.; Ghanian, M. -H.; Hajizadeh-Saffar, E.; Hassan-Aghaei, F.; Mohebi, M.M.; Baharvand, H. Dynamically Capped Hierarchically Porous Microneedles Enable Post-Fabrication Loading and Self-Regulated Transdermal Delivery of Insulin. *Chem Eng J* 2021, 421, 127823, https://doi.org/10.1016/j.cej.2020.127823.

23. Shirzadian, T.; Nourbakhsh, M.S.; Fattahi, A.; Bahrami, G.; Mohammadi, G. Characterization and Optimization of De-Esterified Tragacanth-Chitosan Nanocomposite as a Potential Carrier For Oral Delivery of Insulin: In Vitro and Ex Vivo Studies, *J. Biomed. Mater. Res. Part A* 2021, 109, 2164–2172, https://doi.org/10.1002/jbm.a.37202.

24. Chen, X.; Yu, H.; Wang, L.; Shen, D.; Amin, B.u.l.; Feng, J.; Zhang, Q.; Xiong, W. Microneedle Patch Prepared from a Hydrogel by a Mild Method for Insulin Delivery. *Chem Nano Mat* 2021, 7, 1230–1240, https://doi.org/10.1002/cnma.202100288.

25. Astolfi, P.; Giorgini, E.; Perinelli, D.R.; Vita, F.; Adamo, F.C.; Logripppo, S.; Parlapiano, M.; Bonacucina, G.; Pucciarelli, S.; Francescangeli, O.; Vaccari, L.; Pisani, M. Cubic and Hexagonal Mesophases for Protein Encapsulation: Structural Effects of Insulin Confinement. *Langmuir* 2021, 37, 10166–10176, https://doi.org/10.1021/acs.langmuir.1c01587.

26. Dey, G.R.; Saha, A. Surface Engineered PLGA Nanoparticle for Threshold Responsive Glucose Monitoring and "Self-Programmed" Insulin Delivery. *ACS Biomater Sci Eng* 2021, 7, 4645–4658, https://doi.org/10.1021/acsbiomaterials.1c00830.

27. Chen, Y.; Song, H.; Huang, K.; Guan, X. Novel Porous Starch/Alginate Hydrogels for Controlled Insulin Release with Dual Response to pH and Amylase. *Food Funct* 2021, 12, 9165–9177, https://doi.org/10.1039/D1FO01411K.

28. Zhang, Y.; Xiong, G.M.; Ali, Y.; Boehm, B.O.; Huang, Y.Y.; Venkatraman, S. Layer-by-layer Coated Nanoliposomes for Oral Delivery of Insulin. *Nanoscale* 2021, 13, 776–789, https://doi.org/10.1039/D0NR06104B.

29. Villines, T.C.; Kim, A.S.; Gore, R.S.; Taylor, A.J. Niacin: The Evidence, Clinical Use, and Future Directions. *Curr Atheroscler Rep* 2021, 14, 49–59, https://doi.org/10.1007/s11883-011-0212-1.
30. Poynten, A.M.; Gan, S.K.; Kriketos, A.D.; O’Sullivan, A.; Kelly, J.J.; Ellis, B.A.; Chisholm, D.J.; Campbell, L.V. Nicotinic Acid–Induced Insulin Resistance is Related to Increased Circulating Fatty Acids and Fat Oxidation but not Muscle Lipid Content. *Metabolism* 2003, 52, 699–704, https://doi.org/10.1016/S0026-0495(03)00030-1.

31. Kumar, R.; Kumar, A.; Chauhan, G.S. Pectin-Based Hydrogel as Colon Specific Delivery Carries for Mebeverine Hydrochloride. *Trends Carbohydr Res* 2010, 2, 45–51.

32. Kumar, R.; Kumar, A.; Kumar, J.; Chauhan, S.; Chauhan, G.S. Mechanism of Sazalopyrinfrom Pectin Based Hydrogel: An in Vitro Study. *Trends Carbohydr Res* 2009, 1, 21–29.

33. Thakur, S.; Chauhan, G.S.; Ahn, J.-H. Synthesis of Acryloyl Guar Gum and Its Hydrogel Materials for Use in the Slow Release of L-DOPA and L-Tyrosine. *Carbohydr Polym* 2009, 76, 513–520, https://doi.org/10.1016/j.carbpol.2008.11.012.

34. Jamwal, S.; Ram, B.; Ranote, S.; Dharela, R.; Chauhan, G.S. New Glucose Oxidase-Immobilized Stimuli-Responsive Dextran Nanoparticles for Insulin Delivery. *Int J Biol Macromol* 2019, 123, 968–978, https://doi.org/10.1016/j.ijbiomac.2018.11.147.

35. Jamwal, H.S.; Chauhan, G.S. Designing Silica-Based Hybrid Polymers and their Application in the Loading and Release of Fluorescein as a Model Drug and Diagnostic Agent. *Adv Polym Technol* 2018, 37, 411–418, https://doi.org/10.1002/adp.21681.

36. Anamica, Pande, P.P. Polymer Hydrogels and their Applications. *Int J Mater Sci* 2017, 12, 11–14.

37. Peppas, N.A.; Bures, P.; Leobandung, W.; Ichikawa, H. Hydrogels in Pharmaceutical Formulations. *Eur J Pharm Biopharm* 2000, 50, 27–46, https://doi.org/10.1016/s0939-6411(00)00090-4.

38. Kipcak, A.S.; Ismail, O.; Doymaz, I.; Piskin, S. Modelling and Investigation of the Swelling Kinetics of Acrylamide-Sodium Acrylate Hydrogel. *J Chem* 2014, Article ID 281063, 1–8, http://dx.doi.org/10.1155/2014/281063.

39. He, L.; Liang, H.; Lin, L.; Shah, B.R.; Li, Y.; Chen, Y.; Li, Bin. Green-Step Assembly of Low Density Lipoprotein/Sodium Carboxymethyl Cellulose Nanogels for Facile Loading and pH-Dependent Release of Doxorubicin. *Colloids Surf B Biointerfaces* 2015, 126, 288–296, https://doi.org/10.1016/j.colsurfb.2014.12.024.

40. Tiwari, S.; Sohrab, M. Enhancement of Dissolution Rate of Aceclofenac Formulation of Aceclofenac-Nicotinic Acid Coprecipal using Water Soluble Polymers Like PVPK-30, HPMC5, SSG and Na-CMC. *Indo Global Journal of Pharmaceutical Sciences* 2015, 5, 154–170.

41. Teng, X.; Xu, H.; Song, W.; Shi, J.; Xin, J.; Hiscox, W.C.; Zhang, J. Preparation and Properties of Hydrogels Based on Pegylated lignosulfonate Amine. *ACS Omega* 2017, 2, 251–259, https://doi.org/10.1021/acsomega.6b00296ACS.

42. Azevedo, J.R.; Sizilio, R.H.; Brito, M.B.; Costa, A.M.B.; Serafini, M.R.; Araujo, A.A.S.; Santos, M.R.V.; Lira, A.A.M.; Nunes, R.S. Physical and Chemical Characterization Insulin-Loaded Chitosan-TPP Nanoparticles. *J Therm Anal Calorim* 2011, 106, 685–689, https://doi.org/10.1007/s10973-011-1429-5.

43. Nichols, M.D.; Scott, E.A.; Elbert, D.L. Factors Affecting Size and Swelling of Poly(ethylene glycol) Microspheres Formed in Aqueous Sodium Sulfate Solutions Without Surfactant. *Biomaterials* 2009, 30, 5283–5291, https://doi.org/10.1016/j.biomaterials.2009.06.032.

44. Liu, C.; Kou, Y.; Zhang, X.; Dong, W.; Cheng, H.; Mao, S. Enhanced Oral Insulin Delivery via Surface Hydrophilic Modification of Chitosan Copolymer Based Self-Assembly Polyelectrolyte Nanocomplex. *Int J Pharm* 2019, 554, 36–47, https://doi.org/10.1016/j.ijpharm.2018.10.068.

45. Boushra, M.; Tous, S.; Fethi, G.; Xue, H-Y.; Wong, H-L. Development of Bi-Polymer Lipid Hybrid Nanocarrier (BLN) to Improve the Entrapment and Stability of Insulin for Efficient Oral Delivery. *Drug Deliv Sci Technol* 2019, 49, 632–641, https://doi.org/10.1016/j.jddst.2019.01.007.

46. Yin, R.; He, J.; Bai, M.; Huang, C.; Wang, K.; Zhang, H.; Yang, Shi-mo.; Zhang, W. Engineering Synthetic Artificial Pancreas Using Chitosan Hydrogels Integrated with Glucose-Responsive Microspheres for Insulin Delivery. *Mater Sci Eng C Mater Biol Appl* 2019, 96, 374–382, https://doi.org/10.1016/j.msec.2018.11.032.

47. Volpatti, L.R.; Burns, D.M. Basu, A.; Langer, R.; Anderson, D.G. Engineered Insulin-Polyacation Complexes for Glucose-Responsive Delivery with High Insulin Loading. *J Control Release 2021*, 338, 71–79, https://doi.org/10.1016/j.jconrel.2021.08.017.

48. Zhang, P.; Zhang, Y.; Liu, C.-G. Polymeric nanoparticles based on carboxymethyl chitosan in combination with painless microneedle therapy systems for enhancing transdermal insulin delivery. *RSC Adv* 2020, 10, 24319–24329, https://doi.org/10.1039/d0ra04460a.
49. Mudassir, J.; Darwis, Y.; Muhamad, S.; Khan, A.A. Self-Assembled Insulin and Nanogels Polyelectrolyte Complex (Ins/NGs-PEC) for Oral Insulin Delivery: Characterization, Lyophilization and In-Vivo Evaluation. *Int J Nanomedicine* **2019**, *14*, 4895–4909, [https://doi.org/10.2147/IJN.S199507](https://doi.org/10.2147/IJN.S199507).